Clinical Trials Browser

Phase 1 × Lung Neoplasms × guadecitabine × Clear all

NCT03220477 2025-08-06

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Phase 1 Active not recruiting

Lung Neoplasms